SIMDAX

This brand name is authorized in Austria, Brazil, Croatia, Cyprus, Estonia, Finland, Hong Kong SAR China, Israel, Lithuania, Mexico, New Zealand, Poland, Romania, Spain, Turkey.

Active ingredients

The drug SIMDAX contains one active pharmaceutical ingredient (API):

1	Levosimendan UNII C6T4514L4E - LEVOSIMENDAN
	Levosimendan enhances the calcium sensitivity of contractile proteins by binding to cardiac troponin C in a calcium-dependent manner. Levosimendan increases the contraction force but does not impair ventricular relaxation.
	Read more about Levosimendan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SIMDAX Injection	MPI, EU: SmPC	Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01CX08	Levosimendan	C Cardiovascular system → C01 Cardiac therapy → C01C Cardiac stimulants excl. cardiac glycosides → C01CX Other cardiac stimulants
Discover more medicines within C01CX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	504118030060017
EE	Ravimiamet	1245899, 1338623, 1661835, 1661846, 1661857, 1661868
ES	Centro de información online de medicamentos de la AEMPS	64154
FI	Lääkealan turvallisuus- ja kehittämiskeskus	560557
HK	Department of Health Drug Office	50409
HR	Agencija za lijekove i medicinske proizvode	HR-H-907457388
IL	מִשְׂרַד הַבְּרִיאוּת	7913
LT	Valstybinė vaistų kontrolės tarnyba	1090666
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	106M2002
NZ	Medicines and Medical Devices Safety Authority	10622
PL	Rejestru Produktów Leczniczych	100340023
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W56216001, W68192001
TR	İlaç ve Tıbbi Cihaz Kurumu	8699228760012